In the third quarter, lower sales of Biogen’s multiple sclerosis (“MS”) drugs are likely to have been offset by sequential revenue growth from new products. Sales of Biogen’s MS drugs like Tecfidera ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results